Navigation Links
Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
Date:10/15/2007

< 0.05).

"These diseases are devastating to patients and their loved ones and we are excited to see more and better therapies become available to ease their suffering," said Richard J. Geswell, President, Crohn's & Colitis Foundation of America.

About the ACT Long-Term Extension

Patients with moderate to severe UC, defined as a baseline Mayo score 6 and 12, who were unresponsive to or intolerant to at least one standard therapy, including corticosteroids, immunosuppressants or 5ASAs, were enrolled in ACT 1 (n=364) or ACT 2 (n=364). The 728 patients were randomized to receive REMICADE 5 mg/kg, REMICADE 10 mg/kg or placebo at weeks 0, 2, 6 and every subsequent 8 weeks through week 22 (ACT 2) or week 46 (ACT 1). Patients were allowed to continue to receive conventional therapy.

Patients who completed treatment through the final infusion visit and who, in the opinion of the investigator, could benefit from continued treatment with REMICADE could enroll in the extension trials. Across multiple sites, one hundred and eighteen (118) patients were entered into the ACT 1 extension and 111 patients were entered into the ACT 2 extension.

During the extension, patients continued to receive the study drug to which they were originally randomized (REMICADE 5 mg/kg, REMICADE 10 mg/kg or placebo) every 8 weeks. Patients in the extension trials were assessed using the Physicians Global Assessment (PGA), which is 1 of 4 measures of disease activity included in the Mayo score. Of the 229 patients who entered the extension, 181 have been followed through one year, and 92 have completed two years. Patients who had responded to placebo also enrolled in

the extension to maintain the blind and continued to receive placebo every 8 weeks.

Overall, REMICADE was generally well tolerated in the long-term extensions, with less than five percent of patients discontinuing therapy due to an adverse event (AE). As previously rep
'/>"/>

Contact: Melissa Katz
215-325-6875
Centocor, Inc.
Source:Eurekalert

Page: 1 2 3 4 5 6

Related biology news :

1. Roche clinical trial registry and results database launched
2. NIAID begins clinical trial of West Nile virus vaccine
3. Compound might defeat African sleeping sickness, clinical trial beginning this month
4. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
5. Dalai Lama, top scientists to discuss science & clinical applications of meditation
6. Stem cells electric abilities might help their safe clinical use
7. Clinical trial to test stem cell approach for children with brain injury
8. New malaria vaccine shows promise in early clinical trial
9. Preclinical study of a new brain tumor therapy
10. Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging
11. Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/7/2015)... GOTHENBURG, Sweden , May 7, 2015 /PRNewswire/ ... new touch fingerprint sensors, FPC1022 and FPC1035, FPC,s ... FPC1022 and FPC1035 are mainly considered for integration ... decreased size gives smartphone OEMs increased possibilities to ... portfolio. The decreased size also improves possibilities for ...
(Date:4/27/2015)... more than four decades, AUVSI,s Unmanned Systems ... event for the unmanned land, sea, and air industries. ... local, national, or trade news organization interested in gathering ... applications of unmanned technologies. The conference will explore the ... and how it will soon impact the lives of ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... a major expansion of a lingua franca used ... organisms. The expansion provides terms that scientists ... occur when a pathogenic or beneficial microbe encounters ... developing new interventions for preventing infections by disease-causing ...
... the University of York has been awarded a Research ... Trust to study the geometry of viruses. , Dr ... Biology and Mathematics, will study the structure and assembly ... strategies. , Viruses have highly symmetrical external ...
... Researchers have long said they won't be able to understand ... ?a map of how billions of neurons are interconnected. Now, ... what many believe to be a major hurdle to preparing ... neuron. , In the March 1 issue of the journal ...
Cached Biology News:Uniform language for describing genes of pathogenic and beneficial microbes 2Uniform language for describing genes of pathogenic and beneficial microbes 3York mathematician probes geometric route to combat viruses 2Deconstructing brain wiring, one neuron at a time 2Deconstructing brain wiring, one neuron at a time 3
(Date:5/20/2015)... May 19, 2015 Research and Markets ... "Global Cell Therapy Market Outlook 2020 " ... therapy in tissue and regenerative medicine is expected to ... options which could help in the growth of deregulated ... but they are unable to form new tissue or ...
(Date:5/20/2015)... 20, 2015 The global genotyping market ... during the forecast period of 2015 to 2020 to ... used in drug discovery and development process and to ... In addition to this,heavy investments by key manufacturers to ... also propelling market growth. Browse 113 market data tables ...
(Date:5/20/2015)... Westport, CT (PRWEB) May 20, 2015 ... the 10th anniversary of its acquisition of Tiger-Sul. ... from Enersul (Calgary Alberta, Canada) in May 2005, H.J. ... line to build it into a comprehensive portfolio of ... the strength of H.J. Baker and the innovation of ...
(Date:5/20/2015)... 20, 2015  Haemonetics Corporation (NYSE: HAE ) ... CEO, will present at The Jefferies 2015 Global Healthcare ... June 1 st , 2015 at 8:30am Eastern time.  ... presentation live via webcast at: http://wsw.com/webcast/jeff88/hae ... HAE ) is a global healthcare company dedicated to ...
Breaking Biology Technology:Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 3
... 11, 2011 The American College of Medical Genetics ... Online Live Learning Center , which will bring online ... This valuable, on-demand resource brings the latest educational programming ... such as the Genetics Review Course and Annual Meeting ...
... the Simple Platform for Learning, is a low-cost ... , eLearning and classroom management. ... educators spend a great deal of time and effort ... that want a system that is easy to use, ...
... YORK, Aug. 11, 2011 Bion Environmental Technologies, Inc. ... notified by the United States Patent and Trademark Office ... Organisms" has been granted.  The new ... nutrient uptake capabilities with respect to the removal of ...
Cached Biology Technology:ACMG Announces New Online Live Learning Center: Will Bring Genetics and Genomics Education to Varied Health Professionals 2The SimPL Learning Management System Supports Compliance in Healthcare Facilities 2Bion Announces New U.S. Patent for Phosphorus Removal 2
... High Five cells (BTI-TN-5B1-4) derived ... have been shown to be capable ... secreted recombinant proteins compared to other ... the following features:- -Rapid doubling time as ...
... Flipper® Racks are ideal for storage and ... These polypropylene racks withstand extreme temperatures, making ... They may also be autoclaved for use ... one side accommodates 0.5ml microcentrifuge tubes, the ...
... comprehensive, cost-effective solution to your TechMate ... quality into both our products and ... chemistries and antibodies that have been ... also includes our competitively priced accessories ...
... consists of universal lysis buffer, PCR mix, ... 100 25 l volume PCR reactions. This ... negative or positive rod and coccus bacteria, ... Cereus, Staphylococcus Aureus, Streptococcus Agalactiae, and etc. ...
Biology Products: